Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 5/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925911 | 1.00 | VNN1 (0.49) | VNN1SPHK2SPHK1CNR2PDK2 | |
| SCHEMBL4916455 | 0.85 | F2 (0.41) | VNN1HSD11B1F2 | |
| SCHEMBL4916459 | 0.85 | F2 (0.41) | VNN1HSD11B1F2 | |
| SCHEMBL19970131 | 0.81 | VNN1 (0.49) | VNN1SPHK2SPHK1CNR2PDK2 | |
| SCHEMBL4927636 | 0.77 | L3MBTL1 (0.53) | VNN1SPHK2SPHK1CNR2PDK2 | |
| SCHEMBL4927632 | 0.77 | L3MBTL1 (0.53) | VNN1SPHK2SPHK1CNR2PDK2 | |
| SCHEMBL9999787 | 0.76 | VNN1 (0.49) | VNN1SPHK2SPHK1CNR2NPC1 | |
| SCHEMBL13570470 | 0.74 | SPHK1 (0.47) | VNN1SPHK2SPHK1CNR2PDK2 | |
| SCHEMBL4928248 | 0.73 | CNR1 (0.53) | VNN1SPHK2SPHK1CNR2PDK2 | |
| SCHEMBL4928259 | 0.73 | CNR1 (0.53) | VNN1SPHK2SPHK1CNR2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| EP-1796681-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | Genmedica Therapeutics SL (ES) | 2007-06-20 | — | — | EP | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| WO-2006013209-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | GENMEDICA THERAPEUTICS SL (ES) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | VNN1 502/4885SPHK2 3951/4885SPHK1 3145/4885 |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | VNN1 702/4885SPHK2 3883/4885SPHK1 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.